[Form 4] Benitec Biopharma Inc. Insider Trading Activity

Rhea-AI Filing Summary

Benitec Biopharma Inc. (BNTC) reported a stock option grant to director and Chief Financial Officer Megan Boston. On 11/18/2025, she received options to purchase 200,000 shares of common stock at an exercise price of $13.53 per share, expiring on 11/18/2035.

The options will vest in 16 substantially equal quarterly installments beginning on March 31, 2026, meaning the award vests gradually over four years. The filing indicates she holds these options directly, reflecting a standard equity-based compensation grant that aligns executive incentives with shareholder interests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boston Megan

(Last) (First) (Middle)

C/O BENITEC BIOPHARMA INC.

3940 TRUST WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (right to buy)	$13.53	11/18/2025		A		200,000		(1)	11/18/2035	Common Stock	200,000	$0	200,000	D

Explanation of Responses:

1. The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026.

	/s/ Megan Boston	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Benitec Biopharma (BNTC) disclose in this Form 4 filing?

Benitec Biopharma disclosed a grant of stock options to director and Chief Financial Officer Megan Boston, reported as a Form 4 insider transaction.

How many stock options were granted to the Benitec Biopharma (BNTC) CFO?

The CFO, Megan Boston, was granted 200,000 stock options to purchase Benitec Biopharma common stock.

What is the exercise price and term of the BNTC stock options granted?

The options have an exercise price of $13.53 per share and an expiration date of 11/18/2035, giving a long-term window to exercise.

When do the Benitec Biopharma (BNTC) CFO options begin vesting and over what period?

The options will vest in 16 substantially equal quarterly installments, starting on March 31, 2026, which equates to four years of vesting.

What is the role of the reporting person in this Benitec Biopharma (BNTC) filing?

The reporting person is identified as a Director and Chief Financial Officer of Benitec Biopharma Inc., indicating an executive and board-level insider.

Is this Benitec Biopharma (BNTC) Form 4 filing an acquisition or a sale of securities?

This Form 4 reflects an acquisition of derivative securities (stock options) by the CFO, rather than a sale of existing shares.